Login
$HIND
$1.53 -$0.05 (3.16%) Close

Company Executives

Officer Age 2025 pay Source
Venkat Nelabhotla Also a director
President and CEO
Title from the Form 4 dated Nov 13, 2025
65 $478,711
Jerry Leonard
Chief Financial Officer
Title from the Form 3 dated Sep 1, 2026
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 4
stated in the proxy; 2 not stated
Average tenure
1.0 years
from year joined
CEO also chairs the board
No
Krishna K. Gupta
Director Age On board Independent Committees Other public boards Pay Source
Krishna K. Gupta
38 2025
1 year
Independent None stated Allurion Technologies (NYSE: ALUR) Not stated
Venkat Nelabhotla
65 2025
1 year
Not stated None stated None stated Paid as CEO
Shiladitya Sengupta
54 2025
1 year
Not stated None stated None stated Not stated
Stash Pomichter
26 2025
1 year
Independent None stated None stated Not stated
Mohanjit Jolly
56 2025
1 year
Independent
Audit Committee · Chair Compensation Committee · Chair
None stated Not stated
John Tincoff
39 2025
1 year
Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Mar 31, 2026
Dr. Shiladitya Sengupta
a member of our Board of Directors
$100,000 per annum
per annum

Consulting agreement with VTI under which Dr. Sengupta provides consulting services for a fee of $100,000 per annum payable quarterly

With Vyome Therapeutics, Inc. (VTI) Open in proxy
Dr. Shiladitya Sengupta
a member of our Board of Directors
$151,939
financial year ended December 31, 2024

Stock awards of VTI received by Dr. Sengupta with an estimated fair value of $151,939

With Vyome Therapeutics, Inc. (VTI) Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support